SCHEMBL16595411

SCHEMBL16595411

O=C(O)C(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.67
▸ CA1 P00915 1/20 0.67
▸ CA2 P00918 1/20 0.67
▸ CA9 Q16790 1/20 0.67
▸ ALDH1A1 P00352 4/20 0.64
▸ LMNA P02545 2/20 0.64
▸ GAA P10253 1/20 0.64
▸ SMN1; SMN2 Q16637 4/20 0.63
▸ MAPK1 P28482 2/20 0.63
▸ AKR1C3 P42330 1/20 0.63
▸ USP2 O75604 1/20 0.63
▸ POLB P06746 1/20 0.61
▸ ALOX15 P16050 1/20 0.60
▸ GLA P06280 1/20 0.60
▸ TSHR P16473 2/20 0.59
▸ HTT P42858 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ SLC6A7 Q99884 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16026460 0.92 CA12 (0.71) CA12CA1CA2CA9ALDH1A1
SCHEMBL632109 0.87 CA12 (0.69) CA12CA1CA2CA9ALDH1A1
SCHEMBL27607283 0.85 AKR1C3 (0.83) CA12CA1CA2CA9ALDH1A1
SCHEMBL5237158 0.82 KMT2A (0.68) CA12CA1CA2CA9ALDH1A1
SCHEMBL1422671 0.81 CA12 (0.67) CA12CA1CA2CA9ALDH1A1
SCHEMBL12332491 0.81 SMN1; SMN2 (0.69) CA12CA1CA2CA9ALDH1A1
SCHEMBL16221494 0.81 CA12 (0.67) CA12CA1CA2CA9ALDH1A1
SCHEMBL10341777 0.80 HSP90AA1 (0.85) CA12CA1CA2CA9ALDH1A1
SCHEMBL10373626 0.79 MAPT (0.77) CA12CA1CA2CA9ALDH1A1
SCHEMBL2951878 0.79 ALDH1A1 (0.66) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912977-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BioMarin Pharmaceutical Inc. (US) 2021-11-24 — — EP disclosed
EP-3046920-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARM INC (US) 2021-08-04 — — EP disclosed
US-10927092-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARM INC (US) 2021-02-23 — — US disclosed
US-20190263775-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARM INC (US) 2019-08-29 — — US disclosed
US-10227323-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. (US) 2019-03-12 — — US disclosed
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2016-08-11 — — US disclosed
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2016-08-11 — — US disclosed
WO-2015042397-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2015-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927092-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 CA12 1477/4885CA1 2021/4885CA2 1801/4885
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 CA12 1477/4885CA1 2021/4885CA2 1801/4885
US-10227323-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 CA12 1477/4885CA1 2021/4885CA2 1801/4885
US-20190263775-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 CA12 1477/4885CA1 2021/4885CA2 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback